Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Shareholders for Armata Pharmaceuticals, Inc. held on June 11, 2026. The filing details the election of directors, advisory votes on executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Director Elections
Shareholders elected seven members to the Board of Directors for one-year terms expiring in 2027. All nominees received significant support, though some faced withheld votes:
- Deborah L. Birx, M.D.: 28,349,266 For; 242,970 Withheld.
- Daniel B. Gilmer, Ph.D.: 28,543,542 For; 48,694 Withheld.
- Jules Haimovitz: 28,350,690 For; 241,546 Withheld.
- Odysseas D. Kostas, M.D.: 28,353,918 For; 238,318 Withheld.
- Robin C. Kramer: 28,537,772 For; 54,464 Withheld.
- Joseph M. Patti, Ph.D.: 28,544,094 For; 48,142 Withheld.
- Sarah Schlesinger, M.D.: 28,354,046 For; 238,190 Withheld.
Broker non-votes totaled 1,257,467 shares for all director elections.
Executive Compensation Advisory Vote
Shareholders approved the compensation of named executive officers on a non-binding advisory basis:
- For: 28,547,283 shares
- Against: 27,765 shares
- Abstaining: 17,188 shares
Compensation Frequency Advisory Vote
Shareholders approved a one-year frequency for future advisory votes on executive compensation:
- One Year: 28,567,809 shares
- Two Years: 2,400 shares
- Three Years: 17,113 shares
Consequently, the Board determined to hold annual advisory votes on executive compensation until the next required frequency vote.
Auditor Ratification
Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026:
- For: 29,842,514 shares
- Against: 6,631 shares
- Abstaining: 558 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder meeting.
Investor Verification Checklist
- Verify the composition of the newly elected Board of Directors and their terms.
- Confirm the Board's decision to conduct annual executive compensation advisory votes.
- Review the full proxy statement for details on the specific compensation packages approved.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2026.